← All candidates
44 insider filings on record.
44 filings on record.
CDTXCidara Therapeutics, Inc.
—
44 insider filings on record.
None of them an open-market buy in the last year.
No price data yet — the yfinance scanner hasn't produced bars for CDTX.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
10% owner
Ra Capital Management, L.p.
Bought $100.00M on Jun 26 — 2,272,727 sh @ $44.00, held indirect, 68% of their stake.
4 of 8 positions beat the S&P
President & CEO
Stein Jeffrey
Bought $100.0K on Nov 10 — 2,500 sh @ $40.01, held indirect, 3.6% of their stake.
No completed positions to measure
Director
Mineo Chrysa
Bought $49.3K on Jun 2 — 2,270 sh @ $21.71, held direct, 100% of their stake.
No completed positions to measure
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
39 more transactions on Pro →Context
Coverage
Cidara Therapeutics (CDTX) Rockets 722% in 2025 on Merck $9.2-Billion MergerInsider Monkey · 01-02Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?Motley Fool · 01-02Cidara Therapeutics (CDTX): Assessing Valuation After a 200% Three‑Month Share Price SurgeSimply Wall St. · 12-18Cidara Therapeutics (CDTX): Assessing Valuation After a 137% One-Month SurgeSimply Wall St. · 11-25
The file stays open
44 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice